Yersinia is a genus of bacteria that includes several species known to cause diseases in humans and animals. We explore developments in anti-bacterial compounds to counteract Yersinia infections, focusing on both traditional antibiotic therapies and novel strategies targeting virulence factors, host-pathogen interactions, and vaccine development. This review evaluates current strategies for the treatment and management of Yersinia infections, outlining key challenges and emerging opportunities for improved clinical outcomes.
Sustainability Statement: Much of this article aligns with the Sustainable Development Goal (SDG) 3: Good Health andWell-being, as Yersinia’s environmental resilience and zoonotic transmission promoteacquisition of resistance genes, increasing the threat of multidrug-resistant outbreaks.Developing alternative anti-Yersinia therapeutics advances SDG 3 by lowering infectionburdens, preserving antibiotic effectiveness, and strengthening public-health preparedness.These efforts have relevance to other SDGs – protecting agriculture and ecosystems (SDG 14:Life Below Water; SDG 15: Life on Land), improving food security and sustainable production(SDG 2: Zero Hunger; SDG 12: Responsible Consumption and Production), reducing dual-userisks (SDG 16: Peace, Justice and Strong Institutions), and mitigating climate-driven pathogenevolution (SDG 13: Climate Action).